| CASE REPORT |
|
| Year : 2018 | Volume
: 10
| Issue : 6 | Page : 286-288 |
|
|
Suspected herpes zoster-associated encephalitis during treatment with oral tofacitinib in alopecia universalis
Anna-Marie Hosking, Margit Juhász, Natasha Atanaskova Mesinkovska
Department of Dermatology, University of California, Irvine, California, USA
Correspondence Address:
Ms. Anna-Marie Hosking
Department of Dermatology, University of California, 118 Med Surge I, Irvine 92697, California
USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijt.ijt_87_18
|
|
|
Systemic administration of Janus kinase inhibitors (JAKis) is associated with adverse events, including serious infections, malignancy, and herpes zoster (HZ). Herein, we report a case of a 17-year-old male with alopecia universalis who developed suspected HZ-associated encephalitis (HZAE) during treatment with oral tofacitinib. Oral tofacitinib was immediately discontinued, and the patient was started on antiviral treatment. We present this case to highlight a serious complication that can arise with oral JAKi therapy. Physicians should have a high index of clinical suspicion for HZAE in any patient presenting with a vesicular rash and concomitant neurologic impairments while systemically immunosuppressed.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
